Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

Similar Items

• Randomized Phase 1 Study of Sequential (“Primed”) vs. Concurrent Decitabine in Combination with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
  od: Palmieri, Raffaele, i dr.
  Izdano: (2020)
• Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
  od: Halpern, Anna B., i dr.
  Izdano: (2018)
• Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
  od: Halpern, Anna B., i dr.
  Izdano: (2017)
• Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
  od: Ciera L. Patzke, i dr.
  Izdano: (2020-02-01)
• Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
  od: Patzke, Ciera L., i dr.
  Izdano: (2020)